IL6 and diffuse large B-cell lymphoma: Prior studies have shown significantly elevated serum IL-6 and IL-10 levels in DLBCL patients compared to healthy individuals (10, 16), with elevated cytokine levels correlating with shorter progression-free survival (PFS) and OS (10).